- Home
- BIAF vs GLMD Comparison
BIAF vs GLMD Comparison
Compare BIAF & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | GLMD |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | Israel |
| Employees | 57 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BIAF | GLMD |
|---|---|---|
| Price | $2.70 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 4.7M |
| Earning Date | 05-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.41 |
| 52 Week High | $13.50 | $2.67 |
Technical Indicators
Market Signals| Indicator | BIAF | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 58.53 |
| Support Level | $1.06 | $0.46 |
| Resistance Level | $3.58 | $0.87 |
| Average True Range (ATR) | 0.42 | 0.10 |
| MACD | -0.21 | 0.02 |
| Stochastic Oscillator | 6.71 | 32.27 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.